Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2022
SABCS 2022
HR-Positive/HER2-Negative Breast Cancer
Analysis of the Randomized STIC CTC Trial in ER-Positive/HER2-Negative Metastatic Breast Cancer: Overall Survival Findings
SABCS 2022
Circulating tumor cell count found to provide utility in treatment selection decision-making.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Elacestrant in Postmenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer: Findings from the SOLTI-1905-ELIPSE Trial
SABCS 2022
Preoperative treatment with elacestrant is associated with relevant biological and molecular responses.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Maintenance Ribociclib and ET Following First-Line Chemotherapy in HR-Positive/HER2-Negative Metastatic Breast Cancer: Findings from the Phase 2 AMICA Trial
SABCS 2022
Ribociclib plus ET shows promising efficacy as maintenance therapy in patients with HR-positive/HER2-negative metastatic breast cancer.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Preoperative Ribociclib and Letrozole versus Chemotherapy in HR-Positive/HER2-Negative Breast Cancer: Findings from a Correlative Analysis of the Phase 2 1402-SOLTI/CORALLEEN Trial Study
SABCS 2022
Ribociclib in combination with letrozole induces potent antiproliferative effects in comparison to chemotherapy in patients with HR-positive/HER2-negative breast cancer.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
CDK Inhibition in ER-Positive/HER2-Negative Metastatic Breast Cancer: Real-World Evidence of the Risk of Disease Progression on First-Line Treatment
SABCS 2022
No significant differences in PFS were found between abemaciclib, palbociclib, and ribociclib in a real-world setting.
Read More ›
PIK3CA-Mutated Breast Cancer
Assessing the Activity of Alpelisib in Pathogenic Breast Cancer Mutations Utilizing Patient-Derived Xenografts
SABCS 2022
In vitro study finds combination approaches with alpelisib in triple-negative breast cancer harboring PIK3CA mutations provide synergistic effect.
Read More ›
PIK3CA-Mutated Breast Cancer
Trial to Assess Alpelisib in Combination with Fulvestrant in PIK3CA-Mutated HR-Positive/HER2-Negative Advanced Breast Cancer
SABCS 2022
Clinical trial assessing the additive benefit of alpelisib to fulvestrant in treatment-refractory HR-positive/HER2-negative ABC currently enrolling patients.
Read More ›
PIK3CA-Mutated Breast Cancer
Assessing the Additive Benefit of Alpelisib to Fulvestrant in Advanced Breast Cancer Across the Gene Mutation Landscape: Findings from a Post Hoc Analysis of the SOLAR-1 Trial
SABCS 2022
Results from the SOLAR-1 study demonstrate that only PIK3CA mutations can predict sensitivity to alpelisib in patients with HR-positive/HER2-negative breast cancer.
Read More ›
PIK3CA-Mutated Breast Cancer
Long-Term Disease Control with Fulvestrant plus Alpelisib in PIK3CA-Mutated HR-Positive/HER2-Negative Advanced Breast Cancer: Findings from Cohort A of the BYLieve Study
SABCS 2022
Findings from Cohort A of the BYLieve study suggest that treatment of HR-positive/HER2-negative breast cancer with PIK3CA mutation drivers with alpelisib plus fulvestrant may lead to long-term disease control.
Read More ›
PIK3CA-Mutated Breast Cancer
Trial to Assess Alpelisib in Combination with Tucatinib in PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
SABCS 2022
Clinical trial assessing alpelisib plus tucatinib in HER2-positive mBC with PIK3CA mutations is currently enrolling patients.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us